中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

华蟾素调控AKT介导的上皮间质转化抑制肝细胞癌肺转移裸鼠模型的作用机制

杨悦 续嗣钰 王珏 杜施霖 张春蕾 宋海燕

引用本文:
Citation:

华蟾素调控AKT介导的上皮间质转化抑制肝细胞癌肺转移裸鼠模型的作用机制

DOI: 10.12449/JCH240919
基金项目: 

上海市青年科技英才扬帆计划项目 (20YF1450000);

龙华医院科技创新项目 (CX202205);

上海市卫生健康委卫生行业临床研究专项 (202040223)

伦理学声明:本研究方案于2019年4月18日经由上海中医药大学附属龙华医院实验动物伦理委员会审批,批号:LHERAW-19017,符合实验室动物管理与使用准则。
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:杨悦、续嗣钰、王珏、杜施霖参与收集数据,资料分析;杨悦负责撰写论文;张春蕾、宋海燕负责课题设计,指导撰写文章并最后定稿。
详细信息
    通信作者:

    张春蕾, clzhang213@163.com (ORCID: 0000-0002-3934-7816)

    宋海燕, songhy@126.com (ORCID: 0000-0003-2155-8110)

Mechanism of action of cinobufotalin in inhibiting lung metastasis of hepatocellular carcinoma by regulating AKT-mediated epithelial-mesenchymal transition in a nude mouse model

Research funding: 

Shanghai Youth Technology Talents Sailing Program (20YF1450000);

Longhua Hospital Technology Innovation Project (CX202205);

Clinical Research Special Project of Shanghai Municipal Health Commission (202040223)

More Information
    Corresponding author: ZHANG Chunlei, clzhang213@163.com (ORCID: 0000-0002-3934-7816); SONG Haiyan, songhy@126.com (ORCID: 0000-0003-2155-8110)
  • 摘要:   目的  研究华蟾素通过调控肝细胞癌(HCC)上皮间质转化(EMT)抑制HCC转移的作用和机制。  方法  将36只6周龄雄性BALB/c裸鼠尾静脉注射MHCC97H细胞建立肝癌肺转移瘤模型,随机分为华蟾素高、低剂量组和对照组。建模当日起分别腹腔注射华蟾素120 μL/kg、60 μL/kg或生理盐水,每周2次。8周后取肺组织行HE染色检测肝癌肺转移率。MHCC97H细胞用华蟾素高、低剂量(2.5 μL/mL、5 μL/mL)干预,通过划痕实验、RT-PCR以及Western Blot检测细胞迁移能力和EMT相关分子的表达。用CoCl2孵育模拟低氧环境诱导MHCC97H细胞,同时加入高、低剂量华蟾素干预,通过划痕实验和Western Blot检测华蟾素对低氧诱导的细胞迁移能力和EMT的影响。使用转录组学分析华蟾素对MHCC97H细胞的效应机制。用Western Blot检验华蟾素干预对MHCC97H细胞的蛋白激酶B(AKT)、磷酸化AKT(P-AKT)表达水平的影响。计量资料多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验,两组间比较采用成组t检验。  结果  华蟾素干预组裸鼠较对照组肝癌肺转移率下降。与对照组相比,华蟾素干预使MHCC97H细胞划痕愈合率减小、上皮型分子表达上调(t=2.860,P<0.05),并使EMT转录因子和基质型分子下调(t值分别为3.545、2.022、2.852、2.341,P值均<0.05)。低氧诱导上调MHCC97H细胞划痕愈合率和基质型分子、EMT转录因子表达水平(P值均<0.05),华蟾素干预逆转EMT变化并抑制划痕愈合(P值均<0.05)。肝癌细胞转录组学分析显示,华蟾素组与对照组存在显著的基因差异,华蟾素主要影响了肿瘤、代谢、免疫和信号传导相关基因表达,其中AKT信号转导通路中的差异基因数量最多。进一步检测发现华蟾素干预可下调HCC 细胞AKT、P-AKT和P-AKT/AKT的水平(t值分别为2.434、3.401、2.258,P值均<0.05)。  结论  华蟾素可抑制肝癌转移,尤其对于低氧环境诱导的肝癌转移具有显著抑制作用,调控AKT信号转导通路介导的HCC细胞EMT可能是其部分作用机制。

     

  • 图  1  华蟾素对裸鼠肝癌肺转移的影响

    注: a,肺组织HE染色(×4);b:肺转移率;c:血清ALT活力(U/L);d:血清肌酐含量(μmol/L)。Control:对照组;HCS-L:低剂量华蟾素组;HCS-H:高剂量华蟾素组。箭头标示HCC转移灶。

    Figure  1.  The effect of Cinobufotalin on lung metastasis of HCC in nude mice

    图  2  华蟾素对肝癌细胞迁移能力的影响

    注: a: 划痕愈合图(×4);b: 3组划痕愈合率比较。Control:对照组;HCS-L:低剂量华蟾素组;HCS-H:高剂量华蟾素组。

    Figure  2.  The effect of Cinobufotalin on the migration ability of HCC cells

    图  3  华蟾素对肝癌细胞EMT相关分子表达水平的影响

    注: a,EMT相关分子mRNA表达水平;b,EMT相关分子蛋白表达水平;c,蛋白表达分析。Control:对照组;HCS-L:低剂量华蟾素组;HCS-H:高剂量华蟾素组; HCS:华蟾素组。

    Figure  3.  The effect of Cinobufotalin on the expression of EMT-related molecules in HCC cells

    图  4  华蟾素对低氧环境诱导的肝癌细胞迁移能力和EMT的影响

    注: a,划痕愈合实验图;b,划痕愈合率;c,EMT相关分子蛋白条带;d,EMT相关分子蛋白分析。Control:对照组;CoCl2:模型组;HCS-L:低剂量华蟾素组;HCS-H:高剂量华蟾素组。

    Figure  4.  The effect of Cinobufotalin on hypoxia-induced cell migration ability and EMT of HCC cells

    图  5  华蟾素干预的HCC细胞转录组学分析

    注: a,对照组和华蟾素组之间的差异基因聚类热图;b,表达量差异火山图;c,核心靶点的 KEGG 富集分析图。

    Figure  5.  Seq-RNA analysis of Cinobufotalin -treated HCC cells

    图  6  华蟾素对肝癌细胞AKT信号通路的调控作用

    注: a. 蛋白条带图;b:蛋白表达分析。Control:对照组;HCS:华蟾素组。

    Figure  6.  The regulatory effect of cinobufotalin on AKT signaling pathway in HCC cells

  • [1] Prospective suRveillance for very Early hepatoCellular cARcinoma(PreCar) expert panel. Expert consensus on early screening strategies for liver cancer in China[J]. Chin Hepatol, 2021, 26( 8): 825- 831. DOI: 10.3969/j.issn.1008-1704.2021.08.001.

    全国多中心前瞻性肝癌极早期预警筛查项目(PreCar)专家组. 中国肝癌早筛策略专家共识[J]. 肝脏, 2021, 26( 8): 825- 831. DOI: 10.3969/j.issn.1008-1704.2021.08.001.
    [2] KONYN P, AHMED A, KIM D. Current epidemiology in hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2021, 15( 11): 1295- 1307. DOI: 10.1080/17474124.2021.1991792.
    [3] CHIN KM, ALLEN JC, TEO JY, et al. Predictors of post-hepatectomy liver failure in patients undergoing extensive liver resections for hepatocellular carcinoma[J]. Ann Hepatobiliary Pancreat Surg, 2018, 22( 3): 185- 196. DOI: 10.14701/ahbps.2018.22.3.185.
    [4] ZHANG YT, LI BP, ZHANG B, et al. LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis[J]. Eur Rev Med Pharmacol Sci, 2018, 22( 19): 6333- 6341. DOI: 10.26355/eurrev_201810_16044.
    [5] PASTUSHENKO I, BLANPAIN C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29( 3): 212- 226. DOI: 10.1016/j.tcb.2018.12.001.
    [6] ZHANG G, ZHANG GY. Upregulation of FoxP4 in HCC promotes migration and invasion through regulation of EMT[J]. Oncol Lett, 2019, 17( 4): 3944- 3951. DOI: 10.3892/ol.2019.10049.
    [7] HUANG YH, HONG WQ, WEI XW. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis[J]. J Hematol Oncol, 2022, 15( 1): 129. DOI: 10.1186/s13045-022-01347-8.
    [8] SHEN JJ. The clinical effect of Cinobufagin injection by transcatheter arterial chemoembolization(TACE) combined with intravenous on treating primary liver cancer(PLC)[J]. J Clin Hepatol, 2009, 25( 3): 207- 209. DOI: 10.3969/j.issn.1001-5256.2009.03.018.

    沈建军. 华蟾素介入栓塞联合静脉注射对原发性肝癌的临床疗效[J]. 临床肝胆病杂志, 2009, 25( 3): 207- 209. DOI: 10.3969/j.issn.1001-5256.2009.03.018.
    [9] YU T, ZHAI XF, LIU Q, et al. Clinical effect and safety of hepatic arterial infusion of cinobufotalin injection combined with lipiodol chemoembolization in treatment of Barcelona Clinic Liver Cancer stage C primary liver cancer[J]. J Clin Hepatol, 2017, 33( 2): 281- 285. DOI: 10.3969/j.issn.1001-5256.2017.02.015.

    于童, 翟笑枫, 刘群, 等. 华蟾素注射液经肝动脉灌注联合碘油栓塞治疗巴塞罗那C期原发性肝癌的效果和安全性[J]. 临床肝胆病杂志, 2017, 33( 2): 281- 285. DOI: 10.3969/j.issn.1001-5256.2017.02.015.
    [10] CHENG L, CHEN YZ, PENG Y, et al. Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells[J]. Tumour Biol, 2015, 36( 8): 5763- 5771. DOI: 10.1007/s13277-015-3245-1.
    [11] LI WQ, PEI SH, ZHANG XJ, et al. Cinobufotalin inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells through down-regulate β-catenin in vitro and in vivo[J]. Eur J Pharmacol, 2022, 922: 174886. DOI: 10.1016/j.ejphar.2022.174886.
    [12] YANG SY, ZHANG JJ, HUANG XY. Mouse models for tumor metastasis[J]. Methods Mol Biol, 2012, 928: 221- 228. DOI: 10.1007/978-1-62703-008-3_17.
    [13] ZHU L, CHEN YX, WEI C, et al. Anti-proliferative and pro-apoptotic effects of cinobufagin on human breast cancer MCF-7 cells and its molecular mechanism[J]. Nat Prod Res, 2018, 32( 4): 493- 497. DOI: 10.1080/14786419.2017.1315575.
    [14] YUAN ZT, SHI XJ, QIU YY, et al. Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin[J]. Oncol Rep, 2017, 37( 3): 1815- 1825. DOI: 10.3892/or.2017.5410.
    [15] GUO N, MIAO YY, SUN MZ. Transcatheter hepatic arterial chemoembolization plus cinobufotalin injection adjuvant therapy for advanced hepatocellular carcinoma: A meta-analysis of 27 trials involving 2, 079 patients[J]. Onco Targets Ther, 2018, 11: 8835- 8853. DOI: 10.2147/OTT.S182840.
    [16] CHEN Z, CHEN HY, LANG QB, et al. Preventive effects of Jiedu Granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial[J]. Chin J Integr Med, 2012, 18( 5): 339- 344. DOI: 10.1007/s11655-012-1083-1.
    [17] WEI YH, YANG CX, YANG GM, et al. Inhibitory effect of downregulating HMGB2 expression on epithelial-mesenchymal transition of liver cancer LM3 cells and its AKT/m TOR signaling pathway mechanism[J]. J Jilin Univ Med Ed, 2024, 50( 1): 143- 149. DOI: 10.13481/j.1671-587X.20240118.

    魏雁虹, 杨晨雪, 杨广民, 等. 下调HMGB2表达对肝癌LM3细胞上皮-间质转化的抑制作用及其AKT/mTOR信号通路机制[J]. 吉林大学学报(医学版), 2024, 50( 1): 143- 149. DOI: 10.13481/j.1671-587X.20240118.
    [18] HAY ED. An overview of epithelio-mesenchymal transformation[J]. Acta Anat, 1995, 154( 1): 8- 20. DOI: 10.1159/000147748.
    [19] DUDAS J, LADANYI A, INGRUBER J, et al. Epithelial to mesenchymal transition: A mechanism that fuels cancer radio/chemoresistance[J]. Cells, 2020, 9( 2): 428. DOI: 10.3390/cells9020428.
    [20] ZHANG Y, WEINBERG RA. Epithelial-to-mesenchymal transition in cancer: Complexity and opportunities[J]. Front Med, 2018, 12( 4): 361- 373. DOI: 10.1007/s11684-018-0656-6.
    [21] AIELLO NM, MADDIPATI R, NORGARD RJ, et al. EMT subtype influences epithelial plasticity and mode of cell migration[J]. Dev Cell, 2018, 45( 6): 681- 695. e 4. DOI: 10.1016/j.devcel.2018.05.027.
    [22] VAUPEL P, MAYER A, HÖCKEL M. Tumor hypoxia and malignant progression[J]. Methods Enzymol, 2004, 381: 335- 354. DOI: 10.1016/S0076-6879(04)81023-1.
    [23] VAUPEL P, HÖCKEL M, MAYER A. Detection and characterization of tumor hypoxia using PO2 histography[J]. Antioxid Redox Signal, 2007, 9( 8): 1221- 1235. DOI: 10.1089/ars.2007.1628.
    [24] LIU ZK, WANG YF, DOU CW, et al. Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma[J]. Theranostics, 2018, 8( 17): 4649- 4663. DOI: 10.7150/thno.26789.
    [25] JU SW, WANG F, WANG YR, et al. CSN8 is a key regulator in hypoxia-induced epithelial-mesenchymal transition and dormancy of colorectal cancer cells[J]. Mol Cancer, 2020, 19( 1): 168. DOI: 10.1186/s12943-020-01285-4.
    [26] CORTI F, NICHETTI F, RAIMONDI A, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives[J]. Cancer Treat Rev, 2019, 72: 45- 55. DOI: 10.1016/j.ctrv.2018.11.001.
    [27] LUO H, YU YY, CHEN HM, et al. The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway[J]. Exp Ther Med, 2019, 17( 1): 99- 106. DOI: 10.3892/etm.2018.6896.
    [28] WU DM, ZHANG T, LIU YB, et al. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling[J]. Cell Death Dis, 2019, 10( 5): 349. DOI: 10.1038/s41419-019-1591-4.
    [29] LIU M, HUANG XD, HAN Z, et al. Effect of cadherin-17 on proliferation and apoptosis of colorectal cancer cells and its PI3K/AKT/mTOR signaling pathway regulatory mechanism[J]. J Jilin Univ(Med Ed), 2023, 49( 4): 1008- 1017. DOI: 10.13481/j.1671-587X.20230423.

    刘蒙, 黄晓东, 韩峥, 等. 钙黏蛋白17对结直肠癌细胞增殖和凋亡的影响及其PI3K/AKT/mTOR信号通路调节机制[J]. 吉林大学学报(医学版), 2023, 49( 4): 1008- 1017. DOI: 10.13481/j.1671-587X.20230423.
    [30] XU T, ZHANG R, DONG ML, et al. Osteoglycin(OGN) inhibits cell proliferation and invasiveness in breast cancer via PI3K/akt/mTOR signaling pathway[J]. Onco Targets Ther, 2019, 12: 10639- 10650. DOI: 10.2147/OTT.S222967.
    [31] YEH YH, WANG SW, YEH YC, et al. Rhapontigenin inhibits TGF-β-mediated epithelial-mesenchymal transition via the PI3K/AKT/mTOR pathway and is not associated with HIF-1α degradation[J]. Oncol Rep, 2016, 35( 5): 2887- 2895. DOI: 10.3892/or.2016.4664.
    [32] LI CY, WANG Q, WANG XM, et al. Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway[J]. Eur J Pharmacol, 2019, 858: 172463. DOI: 10.1016/j.ejphar.2019.172463.
    [33] WANG HY, ZHANG CY, XU LT, et al. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway[J]. Oncotarget, 2016, 7( 15): 20193- 20208. DOI: 10.18632/oncotarget.7935.
    [34] XING SP, YU WX, ZHANG XF, et al. Isoviolanthin extracted from Dendrobium officinale reverses TGF-β1-mediated Epithelial⁻Mesenchymal transition in hepatocellular carcinoma cells via deactivating the TGF-β/smad and PI3K/akt/mTOR signaling pathways[J]. Int J Mol Sci, 2018, 19( 6): 1556. DOI: 10.3390/ijms19061556.
    [35] GHALALI A, YE ZW, HÖGBERG J, et al. PTEN and PHLPP crosstalk in cancer cells and in TGFβ-activated stem cells[J]. Biomed Pharmacother, 2020, 127: 110112. DOI: 10.1016/j.biopha.2020.110112.
  • 加载中
图(6)
计量
  • 文章访问数:  121
  • HTML全文浏览量:  59
  • PDF下载量:  17
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-12-20
  • 录用日期:  2024-01-23
  • 出版日期:  2024-09-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回